These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

64 related articles for article (PubMed ID: 3103387)

  • 21. Abnormal regulation of prolactin release in idiopathic Parkinson's disease.
    Lawton NF; MacDermot J
    J Neurol Neurosurg Psychiatry; 1980 Nov; 43(11):1012-5. PubMed ID: 6777462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prolactin response to repeated intravenous stimuli.
    Spitz IM; Gonen B; Luboshitzky R; Rosen E; Shemesh O
    Horm Metab Res; 1979 Apr; 11(4):319-20. PubMed ID: 110661
    [No Abstract]   [Full Text] [Related]  

  • 23. [Dopamine-receptor stimulants in the treatment of Parkinson's disease (author's transl)].
    Ringwald E; Hirt D; Markstein R; Vigouret JM
    Nervenarzt; 1982 Feb; 53(2):67-71. PubMed ID: 7063089
    [No Abstract]   [Full Text] [Related]  

  • 24. Effects of alpha-methyldopa and its metabolites on prolactin release: in vivo and in vitro studies.
    Wiggins JF; Sved AF; Fernstrom JD
    J Pharmacol Exp Ther; 1980 Feb; 212(2):304-8. PubMed ID: 6766188
    [No Abstract]   [Full Text] [Related]  

  • 25. Brain enkephalin receptors in Parkinson's disease.
    Rinne UK; Rinne JK; Rinne JO; Laakso K; Tenovuo O; Lönnberg P; Koskinen V
    J Neural Transm Suppl; 1983; 19():163-71. PubMed ID: 6321647
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pituitary function and the somatotrophic system in patients with idiopathic Parkinson's disease under chronic dopaminergic therapy.
    Schaefer S; Vogt T; Nowak T; Kann PH;
    J Neuroendocrinol; 2008 Jan; 20(1):104-9. PubMed ID: 18081558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Prolactin stimulation using the metoclopramide test in females taking oral contraceptives].
    Carol W; Lauterbach H; Klinger G; Unger A; Michels W
    Zentralbl Gynakol; 1988; 110(23):1515-21. PubMed ID: 3149100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What has been learnt from study of dopamine receptors in Parkinson's disease?
    Hurley MJ; Jenner P
    Pharmacol Ther; 2006 Sep; 111(3):715-28. PubMed ID: 16458973
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Time-dependent alterations of peripheral immune parameters after nigrostriatal dopamine depletion in a rat model of Parkinson's disease.
    Engler H; Doenlen R; Riether C; Engler A; Niemi MB; Besedovsky HO; del Rey A; Pacheco-López G; Feldon J; Schedlowski M
    Brain Behav Immun; 2009 May; 23(4):518-26. PubMed ID: 19486644
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levodopa in the treatment of Parkinson's disease: current controversies.
    Olanow CW; Agid Y; Mizuno Y; Albanese A; Bonuccelli U; Damier P; De Yebenes J; Gershanik O; Guttman M; Grandas F; Hallett M; Hornykiewicz O; Jenner P; Katzenschlager R; Langston WJ; LeWitt P; Melamed E; Mena MA; Michel PP; Mytilineou C; Obeso JA; Poewe W; Quinn N; Raisman-Vozari R; Rajput AH; Rascol O; Sampaio C; Stocchi F
    Mov Disord; 2004 Sep; 19(9):997-1005. PubMed ID: 15372588
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Opiates, prolactin, and the dopamine receptor.
    Tolis G; Dent R; Guyda H
    J Clin Endocrinol Metab; 1978 Jul; 47(1):200-3. PubMed ID: 263291
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tetrabenazine has properties of a dopamine receptor antagonist.
    Login IS; Cronin MJ; MacLeod RM
    Ann Neurol; 1982 Sep; 12(3):257-62. PubMed ID: 7137960
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Increased secretion of prolactin after inhibition of dopaminergic receptors by metoclopramide in patients with cancer of the prostate].
    Baranowska B; Jeske W; Szymanowski J; Piechna K
    J Urol (Paris); 1983; 89(8):601-5. PubMed ID: 6203986
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Parkinson's disease and the adaptive capacity of the nigrostriatal dopamine system: possible neurochemical mechanisms.
    Hornykiewicz O
    Adv Neurol; 1993; 60():140-7. PubMed ID: 8420131
    [No Abstract]   [Full Text] [Related]  

  • 35. [Neuroendocrine correlations in the pathogenesis and pathology of Parkinson disease].
    Pinessi L; Sabbatini F; De Mattei M; Gentile S
    Minerva Med; 1984 Nov; 75(42):2539-42. PubMed ID: 6096765
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dopamine receptor elevation in denervated tissues.
    Seeman P; Guttman M
    Ann Neurol; 1987 Apr; 21(4):412-5. PubMed ID: 3579228
    [No Abstract]   [Full Text] [Related]  

  • 37. [The dopamine receptor. Target of various diseases].
    Herschel M
    Fortschr Med; 1987 Feb; 105(5):86-8. PubMed ID: 2881870
    [No Abstract]   [Full Text] [Related]  

  • 38. Prolactin and sex hormones levels in males with Parkinson's disease.
    Nitkowska M; Tomasiuk R; Czyżyk M; Friedman A
    Acta Neurol Scand; 2015 Jun; 131(6):411-6. PubMed ID: 25399742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Blood lactate in Parkinson's disease.
    Di Monte D; Tetrud JW; Langston JW
    Ann Neurol; 1991 Mar; 29(3):342-3. PubMed ID: 2042953
    [No Abstract]   [Full Text] [Related]  

  • 40. Plasma cholesterol and Parkinson's disease: is the puzzle only apparent?
    Scigliano G; Ronchetti G; Girotti F
    Mov Disord; 2010 Apr; 25(5):659-60. PubMed ID: 20155795
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.